SHANGHAI – Beike Biotechnology Co. Ltd., a pioneer in China's stem cell industry, has entered a partnership with Altor Bioscience Corp. in a two-part licensing and equity deal. On the front end, Altor will see its coffers increase by $9 million, in a deal worth potentially $200 million in milestones and sales royalties. The agreement gives Beike the rights to develop and commercialize ALT-803, an interleukin-15 based superagonist complex in China, for all human disease indications.